Publications & posters Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts. Filter View all EFX FGF21 MASH Jun 2021 | FROM AKERO THERAPEUTICS Increased adiponectin following efruxifermin treatment is associated with improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NAS Frias, J. et al. American Diabetes Association 81st Scientific Sessions Jun 2021 | FROM AKERO THERAPEUTICS Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin Harrison, S. et al. The International Liver Congress™ 2021 (EASL) Dec 2020 | From Akero Therapeutics FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases Tillman, E., and Rolph, T. Frontiers in Endocrinology Jul 2020 | FROM AKERO THERAPEUTICS AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients Kaufman, A. et al. Cell Reports Medicine Dec 2019 | FROM EXTERNAL EXPERTS Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial Sanyal, A. et al. Lancet Aug 2018 | FROM EXTERNAL EXPERTS A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway Bao, L. et al. British Journal of Pharmacology Jul 2018 | FROM EXTERNAL EXPERTS A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling Shi, S.Y. et al. Scientific Reports Jul 2018 | From External Experts FGF21 gene therapy as treatment for obesity and insulin resistance Jimenez, V., et al EMBO Molecular Medicine Page 4 of 6« First<<...23456>> We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline. View Our Pipeline We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline. View Our Pipeline